1.69
Schlusskurs vom Vortag:
$1.77
Offen:
$1.77
24-Stunden-Volumen:
21.00M
Relative Volume:
1.17
Marktkapitalisierung:
$1.08B
Einnahmen:
$183.88M
Nettoeinkommen (Verlust:
$-85.78M
KGV:
-13.13
EPS:
-0.1287
Netto-Cashflow:
$-110.95M
1W Leistung:
-1.17%
1M Leistung:
+6.96%
6M Leistung:
+32.03%
1J Leistung:
+35.20%
Geron Corp Stock (GERN) Company Profile
Firmenname
Geron Corp
Sektor
Branche
Telefon
(650) 473-7700
Adresse
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GERN
Geron Corp
|
1.69 | 1.13B | 183.88M | -85.78M | -110.95M | -0.1287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-05-08 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-02-27 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-02-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-04-29 | Eingeleitet | TD Cowen | Buy |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2023-09-12 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-28 | Eingeleitet | Goldman | Neutral |
| 2022-10-28 | Eingeleitet | Wedbush | Outperform |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-08-03 | Eingeleitet | Stifel | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-04-09 | Hochstufung | Needham | Hold → Buy |
| 2019-01-31 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-02 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-07-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2016-09-13 | Bestätigt | FBR & Co. | Outperform |
| 2016-09-13 | Bestätigt | FBR Capital | Outperform |
| 2015-12-07 | Bestätigt | Piper Jaffray | Overweight |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-06-12 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-12 | Herabstufung | MLV & Co | Buy → Hold |
| 2013-12-10 | Bestätigt | MLV & Co | Buy |
| 2013-12-10 | Hochstufung | Needham | Hold → Buy |
| 2013-11-08 | Bestätigt | MLV & Co | Buy |
| 2013-10-16 | Eingeleitet | MLV & Co | Buy |
| 2012-08-30 | Eingeleitet | Stifel Nicolaus | Buy |
| 2012-06-28 | Eingeleitet | Needham | Hold |
Alle ansehen
Geron Corp Aktie (GERN) Neueste Nachrichten
Geron (GERN) grants 2.5M stock options to chief legal officer - Stock Titan
Geron (GERN) EVP and Chief Legal Officer files initial Form 3 insider report - Stock Titan
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech upside? - AD HOC NEWS
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf - Yahoo Finance
Geron names Timothy Williams as chief legal officer By Investing.com - Investing.com South Africa
Geron names Timothy Williams as chief legal officer - Investing.com
Geron taps former Vanda counsel Timothy Williams for top legal post - Stock Titan
Geron Corp stock (US3741631036): Is imetelstat approval the real test for biotech investors now? - AD HOC NEWS
History Review: Can Geron Corporation be the next market leader2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
GERN Stock Price, Quote & Chart | GERON CORP (NASDAQ:GERN) - ChartMill
Board agenda in new Geron (NASDAQ: GERN) 2026 virtual annual meeting proxy - Stock Titan
Geron Corporation (GERN) stock price, news, quote and history - Yahoo Finance UK
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form DEF 14AOther definitive proxy statements - ADVFN
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Geron executives to speak April 13 at Needham healthcare webcast - Stock Titan
Is Geron (GERN) Quietly Reframing Its Oncology Commercialization Strategy With New Board Appointments? - simplywall.st
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron (NASDAQ:GERN) Trading Up 9.7%What's Next? - MarketBeat
Geron Corporation’s Strategic Moves Amplify Stocks in Q1 2026 - StocksToTrade
Market Recap: Can Geron Corporation deliver consistent dividendsPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Aug Highlights: Can Geron Corporation be the next market leaderExit Point & Breakout Confirmation Trade Signals - baoquankhu1.vn
GERN Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (NASDAQ:GERN) - ChartMill
Geron Corp Stock: Biotech Investor Focus on RYTELO Commercialization and Valuation Gap Amid Market V - AD HOC NEWS
Geron Adds Biopharma Veterans As RYTELO Focus And Valuation Draw Attention - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Geron (GERN) Valuation After Recent Share Price Weakness - simplywall.st
Geron Corporation Form 8-K Filing Details for March 25, 2026: Company Information, Stock Symbol, and SEC Compliance 16 - Minichart
Vanguard (NASDAQ: GERN) discloses 0 share ownership after realignment - Stock Titan
Geron (NASDAQ: GERN) director granted 270,000 stock options at $1.57 strike - Stock Titan
Geron (GERN) director Constantine Chinoporos files initial Form 3 - stocktitan.net
Geron (GERN) grants director 270,000 stock options at $1.57 - Stock Titan
Geron (GERN) director Patricia Andrews submits initial insider ownership filing - Stock Titan
Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors - Investing.com
Geron adds two directors with commercial expertise to board - Investing.com
[8-K] GERON CORP Reports Material Event - Stock Titan
Geron Announces Appointment of New Members to its Board of Directors - ChartMill
Geron Corp stock advances on imetelstat FDA approval momentum and pipeline updates - AD HOC NEWS
Geron's cancer screening patent rejected as non-patentable under Indian law - MLex
Geron (NASDAQ:GERN) Trading Up 8.6%Here's What Happened - MarketBeat
Geron’s Strategic Push: RYTELO’s Rising Global Ambitions - StocksToTrade
Levi & Korsinsky Notifies Shareholders of Geron Corporation(GERN) - The National Law Review
Geron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Six new Geron hires get stock options on 956,250 shares - Stock Titan
Geron (GERN) reports Q4 loss, misses revenue estimates - MSN
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference - MarketBeat
Geron (NASDAQ:GERN) Shares Up 8.5%Should You Buy? - MarketBeat
Almitas Capital LLC Buys Shares of 946,323 Geron Corporation $GERN - MarketBeat
Geron (NASDAQ:GERN) Stock Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Finanzdaten der Geron Corp-Aktie (GERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):